Together with the notion that uncoupling MDM2–p53 interaction equally drives stabilization of wild type and mutant-p53 proteins, this may represent a very major concern to the straightforward application of MDM2-antagonists to cancer therapy, unless equally potent p53-independent approaches are developed and tested in combination therapy. This evidence concerns the gene TP53 and cancer.